These are top 10 stocks traded on the Robinhood UK platform in July
Investing.com - Cantor Fitzgerald has reiterated its Overweight rating and $104.00 price target on Viking Therapeutics (NASDAQ:VKTX), a $3.7 billion market cap biotech company, following its second quarter 2025 earnings report. According to InvestingPro data, analyst consensus remains strongly bullish with price targets ranging from $33 to $125, suggesting significant upside potential. The company maintains a "GOOD" Financial Health score, supported by strong liquidity metrics.
Viking Therapeutics did not narrow the timing for its Phase 2 data on oral VK2735, maintaining its previous guidance of second half 2025 for the release of these results.
According to Cantor Fitzgerald, the company’s decision not to provide more specific timing is due to limited visibility on data cleaning and ultimate timing of receipt of data from the contract research organization (CRO).
The research firm noted that Viking Therapeutics has "every incentive" to announce these data as soon as they become available, as the results will inform dosing decisions for the Phase 1 maintenance study.
The Phase 1 maintenance study is planned to begin in the third quarter of 2025, making the timing of the Phase 2 data particularly relevant for the company’s clinical development timeline.
In other recent news, Viking Therapeutics reported a second-quarter loss of $0.58 per share, which was larger than anticipated by analysts. The reported loss exceeded both the consensus estimate of $0.44 and H.C. Wainwright’s forecast of $0.42 per share. The higher-than-expected loss was primarily due to increased research and development expenses, which totaled $60.2 million, surpassing the analyst’s projection of $42.04 million. Despite the earnings miss, H.C. Wainwright has reiterated its Buy rating for Viking Therapeutics, maintaining a price target of $102. This suggests continued confidence in the company’s long-term potential. The company’s stock rose by 4.05% in aftermarket trading, indicating investor optimism about future growth prospects and ongoing developments in the obesity treatment sector. These recent developments highlight the mixed reactions from the market and analysts regarding Viking Therapeutics’ financial performance and future outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.